Merus N.V. (MRUS) Tops Q3 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. NEST:IN
10. AA

Go back to Merus N.V. (MRUS) Tops Q3 EPS by 8c

Merus Announces Financial Results for the Third Quarter and Provides Business Update

November 3, 2022 7:51 AM EDT

 Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enrollment in eNRGy trial to support potential BLA filing Clinical update of petosemtamab planned for first half of 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter that ended September 30, 2022 and provided a... More